DPP4 and neoplasm: Since our present data indicate that both U16-3 mAb and U38-8 mAb can clearly stain CD26 in the bone or on tumor cells in calcified tissues (Fig 6B and 6C), these mAbs are expected to contribute to future CD26-related research involving normal tissues and tumor/inflammatory lesions accompanied by calcification.